Product Description
Refametinib potently inhibits MEK1/2, part of the MAPK signaling pathway. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/27975152/)
Mechanisms of Action: MAP2K Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Hepatocellular Carcinoma|Adenocarcinoma|Biliary Tract Cancer|Colorectal Cancer|Oncology Unspecified
Phase 1: Oncology Solid Tumor Unspecified|Colorectal Cancer|Healthy Volunteers|Breast Cancer|Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ARES | P2 |
Active, not recruiting |
Colorectal Cancer |
2017-09-26 |
|
| Refametinib in combination with sorafenib in RAS mutant HCC | P2 |
Completed |
Hepatocellular Carcinoma |
2017-03-13 |
|
| JapicCTI-142425 | P2 |
Completed |
Hepatocellular Carcinoma |
2016-12-31 |
|
| JapicCTI-132357 | P2 |
Completed |
Hepatocellular Carcinoma |
2016-12-31 |